Note

石四药集团(02005):依托咪酯获国家药品监督管理局批准登记成为在上市制剂使用的原料药

· Views 25

石四药集团(02005)发布公告,集团的依托咪酯已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。

依托咪酯主要用作麻醉药,在国内被列入受管制的第二类精神药品目录。目前,集团已持有国内精神药品生产许可证并符合相关的生产管理规定。

Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.

FOLLOWME Trading Community Website: https://www.followme.com

If you like, reward to support.
avatar

Hot

No comment on record. Start new comment.